Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 7, 2024

MannKind to Present at 2024 UBS Healthcare Conference

GlobeNewswire November 5, 2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

GlobeNewswire November 4, 2024

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

GlobeNewswire October 31, 2024

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

GlobeNewswire September 30, 2024

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

GlobeNewswire September 18, 2024

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 10, 2024

MannKind to Present at Upcoming Conferences

GlobeNewswire August 27, 2024

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

GlobeNewswire August 14, 2024

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

GlobeNewswire August 7, 2024

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

GlobeNewswire July 31, 2024

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

GlobeNewswire July 30, 2024

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions

GlobeNewswire June 22, 2024

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

GlobeNewswire June 5, 2024

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

GlobeNewswire May 29, 2024

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PR Newswire May 29, 2024

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

GlobeNewswire May 8, 2024

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

GlobeNewswire May 6, 2024

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

GlobeNewswire May 1, 2024

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

GlobeNewswire April 30, 2024